Abstract
Cirrhotic cardiomyopathy is a cardiac condition observed in patients with cirrhotic regardless of the etiologies. It is characterized by the impaired systolic response to physical stress, diastolic dysfunction, and electrophysiological abnormalities, especially QT interval prolongation. Its pathophysiology and clinical significance has been a focus of various researchers for the past decades. The impairment of β-adrenergic receptor, the increase in endogenous cannabinoids, the presence of cardiosuppressants such as nitric oxide and inflammatory cytokines are the proposed mechanisms of systolic dysfunction. The activation of cardiac renin-angiotensin system and salt retention play the role in the development of cardiac hypertrophy and impaired diastolic function. QT interval prolongation, which is observed in 40–50 % of cirrhotic patients, occurs as a result of the derangement in membrane fluidity and ion channel defect. The increased recognition of this disease will prevent the complications of overt heart failure after procedures such as transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation. Better understandings of the pathogenesis and pathology of cirrhotic cardiomyopathy is crucial in developing more accurate diagnostic tools and specific treatments of this condition.
Similar content being viewed by others
Abbreviations
- AC:
-
Adenylate cyclase
- ATP:
-
Adenosine triphosphate
- cAMP:
-
Cyclic adenosine monophosphate
- cGMP:
-
Cyclic guanosine monophosphate
- CO:
-
Carbon monoxide
- HO:
-
Heme oxygenase
- MPTPs:
-
Mitochondrial permeability transition pores
- NO:
-
Nitric oxide
- NOS:
-
Nitric oxide synthase
- PDE2 :
-
Prostaglandin E2
- PKA:
-
Protein kinase A
- TNF-α:
-
Tumor necrosis factor-α
References
Kowalski H, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 1953;32:1025–1033
Gould L, Shariff M, Zahir M, Di LM. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48:860–868
Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984;54:852–855
Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326–332
Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68–74
Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996;23:1128–1134
Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268–278
Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179–190
Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011;43:1649–1653
Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010;56:539–549
Myers RP, Lee SS: Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;S44-S52
Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007;2:15
Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001;49:268–275
Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974;49:754–760
Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9–15
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439–447
Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105–110
Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210–1218
Moller S, Henriksen JH. The systemic circulation in cirrhosis. In Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell; 2005. 139–155
Brum PC, Kosek J, Patterson A, Bernstein D, Kobilka B. Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am J Physiol Heart Circ Physiol 2002;283:H1838–H1845
Gerbes AL, Remien J, Jungst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986;1:1409–1411
Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990;4:2881–2889
Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990;12:481–485
Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451–459
Baldassarre M, Giannone FA, Napoli L, Tovoli A, Ricci CS, Tufoni M, et al. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int 2013;33:1298–1308
Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005;146:315–323
Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2010;53:298–306
van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996;24:747–752
Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937–944
Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) 2002;102:213–222
Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009;3:294–304
Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol 2001;280:G68–G74
Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, et al. Ca2+ influx-induced sarcoplasmic reticulum Ca2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res 2005;97:1009–1017
Zaky A, Lang JD. Cirrhosis-associated cardiomyopathy. J Anesth Clin Res 2012;3:1–7
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–133
Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int 2013;33:1158–1165
Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2013;11(3):177–186
Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995;107:1467–1469
Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743–748
Lunseth JH, Olmstead EG, Forks G, et al. A study of heart disease in one hundred and eight hospitalized patients dying with portal cirrhosis. AMA Arch Intern Med 1958;102:405–413
Schenk EA, Cohen J. The heart in chronic alcoholism. Clinical and pathologic findings. Pathol Microbiol (Basel) 1970;35:96–104
Glenn TK, Honar H, Liu H, ter Keurs HE, Lee SS. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol 2011;55:1249–1255
Borbely A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009;104:780–786
Fields NG, Yuan BX, Leenen FH. Sodium-induced cardiac hypertrophy. Cardiac sympathetic activity versus volume load. Circ Res 1991;68:745–755
Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000;141:1901–1904
Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11–34
Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998;98:2621–2628
Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422–433
Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci 2013;58:3029–3036
Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28–34
Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003;23:243–248
Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461–467
Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991;12:207–216
Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513–520
Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994;267:G87–G93
Gazawi H, Ljubuncic P, Cogan U, Hochgraff E, Ben-Shachar D, Bomzon A. The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochem Pharmacol 2000;59:1623–1628
Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273:G537–G544
Bouchard RA, Clark RB, Giles WR. Effects of action potential duration on excitation–contraction coupling in rat ventricular myocytes. Action potential voltage-clamp measurements. Circ Res 1995;76:790–801
Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest 2003;112:810–815
Trevisani F, Di MA, Zambruni A, Biselli M, Santi V, Erroi V, et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012;32:1510–1515
Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004;40:239–246
Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010;52:811–813
Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005;100:1110–1116
Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, et al. Post-liver transplantation myocardial dysfunction. Liver Transplant Surg 1998;4:399–403
Acknowledgements
This study is supported by K08 AA016570 from the NIH/NIAAA, 1I01CX000361-01 from the Veterans Affairs Research and Administration, Indiana University Research Support Fund Grant, and W81XWH-12-1-0497 from United States Department of Defense (All to S.L.).
Compliance with ethical requirements and Conflict of interest
All authors comply with the ethical policies in preparation of this manuscript. Maneerat Chayanupatkul and Suthat Liangpunsakul have nothing to disclose regarding conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chayanupatkul, M., Liangpunsakul, S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 8, 308–315 (2014). https://doi.org/10.1007/s12072-014-9531-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-014-9531-y